The first results published from the IPERGAY study, a trial of
pre-exposure prophylaxis (PrEP) in gay men taking place in France and Quebec,
Canada, appear to indicate excellent adherence to a novel ‘pre-and-post’ intermittent PrEP
strategy designed to save money and reduce time spent taking PrEP unnecessarily. The results were presented at the 20th International AIDS Conference (AIDS 2014), taking place in Melbourne, Australia.
IPERGAY enrolled its first participant in February 2012, but
because recruitment to this placebo-controlled trial has been slow, it is not
expected to produce final efficacy results till late 2016, though interim
results may be available before that.
It uses a novel intermittent-PrEP strategy: participants take
two tenofovir/emtricitabine (Truvada)
pills from 2 to 24 hours before anticipated sex. If they then actually have
sex, they take one pill 24 hours after sex and another a further 24 hours after
that. This strategy is derived from animal studies of drug concentration in tissues,
though presenter Jean-Michel Molina did comment that “We insisted on two doses
after sex in order to ensure that the volunteers took at least one of them”.
Adherence as measured by computer-assisted self-interview,
pill count and by drug concentration in the blood was assessed in the first 129
participants to be randomised, between February 2012 and February 2013, with a
mean follow-up time of 8.3 months.
The average age of the 129 men was 35; nearly all were white
and defined as gay (only 4% as bisexual) and 17% were circumcised.
This was quite a sexually active group. The median number of
episodes of anal sex (with or without condoms) was two a week and the average
number of partners in two months was ten.
Eighty-one per cent of participants said in self-interview
that they used PrEP the last time they had sex, though only 53% said they took all
doses as required. Results were similar in face-to-face interviews: 76% of
participants stated that they had taken PrEP the last time they had sex, while
11% said they took it ‘often’.
Participants were issued with enough Truvada to take daily PrEP: only four individuals said they actually
did take it daily, but pill counts showed that the average number of pills
taken per month was 15.4, so participants were on PrEP almost exactly half the
Researchers have grown used to being wary of adherence as
measured by self-report and pill count, and other studies seemed to indicate
that adherence was likely to be higher if
PrEP was dosed daily rather than intermittently; in particular, a
study in Kenya found that participants
had difficulty remembering to take the post-sex doses in intermittent PrEP.
In the case of IPERGAY, however, drug levels in blood appeared
to indicate good adherence too. The proportion of participants with tenofovir detected
in their blood plasma varied from 82 to 91% per two-monthly visit, and the
proportion with detectable emtricitabine from 75 to 84%. These levels so far
show no sign of declining with time.
A consistent 4 to 6% of participants in the placebo arm also had detectable
levels of one or both drugs in the blood: half of these were participants who
had taken post-exposure prophylaxis (allowed in the protocol), but the other
few individuals may have taken PrEP ‘informally’.
What does ‘detectable in the blood’ actually mean in the
context of an intermittent PrEP regimen? Jean-Michel Molina said that the assay
used could detect the drugs up to seven days after they were taken, so this means
that perhaps 80 to 85% of IPERGAY participants had taken PrEP at least once in the
week before a sample was taken.
IPERGAY is also measuring drug concentrations in participants’
hair: this is a better way of measuring consistency of use over weeks or months.
The researchers have found difficulty in collecting hair samples from participants
(only scalp hair will do, and often participants like to be bald or cropped)
but they did collect 59 samples from 38 participants. Detectable tenofovir was
only found in 51% of samples, and 14% of samples from placebo recipients also
contained tenofovir, so the reliability of this method is yet to be proven.
Jean-Michel Molina was asked about side-effects reported by
participants. He said that so far on the IPERGAY regimen there were few reports
of nausea, stomach disturbance or headache, which have been reported quite frequently
by participants in other trials in the first few weeks on PrEP.
IPERGAY has now recruited all 350 participants required for
its pilot phase and is going to move to an expanded phase. Obviously the adherence
results tell us nothing about likely efficacy, but they at least indicate that
the novel regimen used in IPERGAY is proving to be acceptable to trial